查詢結果分析
來源資料
頁籤選單縮合
題 名 | 市售海芙蓉類藥材之藥用植物學考察=Pharmacobotanical Studies of Crude Drug Hai-Fu-Ro Commercially Available on the Market |
---|---|
作 者 | 柯裕仁; 謝文全; 邱年永; 陳忠川; 張永勳; | 書刊名 | 中國醫藥學院雜誌 |
卷 期 | 8:4 1999.12[民88.12] |
頁 次 | 頁7-15 |
分類號 | 376.15 |
關鍵詞 | 海芙蓉; 藥用植物; 民間藥; 臺灣; 金門; Hai-fu-ro; Medicinal plants; Folk medicine; Taiwan; Kinmen; |
語 文 | 中文(Chinese) |
中文摘要 | 海芙蓉是臺灣、閩南地區著名之藥材,以其能袪除風濕、活血化瘀、消腫解毒, 能治療風濕、關節炎、筋骨酸痛、跌打損傷等諸症,而常被中醫師或民間驗方來使用,臨床 使用量甚大。本類藥材之來源,在臺灣地區以藍雪科石蓯蓉屬 Limonium 植物之根或全草為 主;但金門、馬祖等地區之海芙蓉卻是以藜科濱藜屬 Atriplex 植物之全草為主,另尚有菊 科芙蓉菊屬 Crossostephium 之根或全草亦曾被稱為海芙蓉來使用,造成藥材同名異物、一 名數物的混雜現象。藥材來源之真偽,品質之良窳,在臨床使用上,影響療效至鉅。海芙蓉 藥材雖使用已久,又在金、馬地區成為名產也有多年,卻未曾見文獻報告其來源之複雜性, 因此實有必要加以調查,以釐清該植物性藥材之基原,並提供後續藥學研究之基礎。 本研究係對目前臺、澎、金、馬地區市售之海芙蓉藥材及其來源植物進行調查及採集,經藥 用植物學鑑定結果,發現計有黎科 1 屬 3 種;藍雪科 1 屬 3 種及菊科 1 屬 1 種,共計 3 科 3 屬 7 種的植物均被稱為海芙蓉而於市上廣為銷售或使用。 為釐清此 7 種植物之基 原,並從其學名、別名、分布、形態、藥用部位、效用、成分、藥理等要點來比較其異同, 而進行是類藥材藥用植物學之考察。 從藥用植物學考察上,我們發現大部分的海芙蓉類藥材仍少有在生藥學、植物化學及藥理學 上之文獻報告,有待再進一步去研究探討。 |
英文摘要 | Hai-Fu-Ro (sea hibiscus; 海芙蓉) is a famous folk medicine in Taiwan and Southern Fukien. It has been reported to have anti-cold, anti-rheumatic, bloodcirculation promoting, anti-coagulant, anti-dotal and anti-swelling effects, and has often been used to treat rheumatism, arthritis, musclar pain, trauma, etc. by herbalists and Chinese medicine doctors. The origins of crude drug Hai-Fu-Ro mainly used in the Taiwan Area are root or whole herb of Limonium genus (石蓯蓉屬 ) of Plumbaginaceae (藍雪科 ). But, We found that the drug popularly sold and used in Kinmen, Matsu islands are Atriplex genus (濱藜屬 ) of Chenopodiaceae (藜科 ). Besides this, there is Crossostephium chinensis (芙蓉菊 ) of Compositae (菊科 ), which is also a homonymous generic of the drug. These complexity of the origins of this crude drug inevitably affects drug quality and clinical efficacy, and ought to be clarified for the pharmaceutical basis. For this reason, we started with the pharmacobotanical study to identify the sources of different specimen, and found that there were totally 7 species of 3 genera in 3 families with 3 species of 1 genus in Plumbaginaceae, 3 species of 1 genus in Chenopodiaceae and 1 species of 1 genus in Compositae were sold with the same name on the market. We reviewed the recent literatures of pharmaceutical botany, pharmacognosy, phytochemistry and pharmacology to elucidate the utilization of the drug. From pharmaceutical evaluation, we concluded that most original plants of this homonymic drug are not well-documented and further investigation is absolutely necessary. |
本系統中英文摘要資訊取自各篇刊載內容。